Nivolumab after mismatched bone marrow transplant for sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial studies nivolumab (an immune treatment) in people with sarcoma who already had a partially mismatched bone marrow transplant. It may help the new immune system recognize and attack cancer, and researchers will also watch closely for side effects like GVHD (immune reaction after transplant) and autoimmune problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 months and 50 years old when you join the study.
- You have biopsy-proven sarcoma (or another solid tumor) expected to have a poor long-term outcome.
- You are well enough to participate: Karnofsky score ≥50 (if over 16) or Lansky score ≥60 (if 16 or younger).
- You already had a reduced-intensity haploidentical (partially mismatched) bone marrow transplant, and you’ve fully recovered from the worst early transplant side effects.
- You must be off serious immune reactions from the transplant: no severe past GVHD, and if you had only mild GVHD (Grade II or less), you must have stopped immune-suppressing medicines for at least 2 weeks.
- You must be able to provide a tumor sample (a new biopsy if safe/easy, or stored tissue if not) before treatment and again around Cycle 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a combination of two drugs, palbociclib and pembrolizumab, in people with certain types of advanced sarcoma (cancer of the soft tissues) that have continued to grow despite prior treatment. It aims to see if this combination can shrink tumors or slow down the cancer.
This trial tests a new approach using a special type of transplant (with cells from a half-matched family donor) plus a drug called zoledronic acid. It is for children and young adults with certain solid tumors that have not responded to standard treatments.
This trial tests a new immunotherapy drug (nivolumab) in children and adults with certain hard-to-treat solid tumors. It may help if standard treatments haven't worked or aren't an option.
This trial tests an infusion of activated NK cells (a type of immune cell) to treat sarcomas that are still detectable or not responding well to standard treatment. If you qualify, you may receive this cell therapy while doctors closely check your organ function and heart strength.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.